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Advanced glycation end products (AGEs) have been implicated in the development of diabetic complications, including diabetic
nephropathy. KIOM-79, an 80% ethanolic extract obtained from parched Puerariae Radix, gingered Magnolia Cortex, Glycyrrhiza
Radix and Euphorbia Radix, was investigated for its eﬀects on the development of renal disease in Zucker diabetic fatty rats, an
animal model of type 2 diabetes. In vitro inhibitory eﬀect of KIOM-79 on AGEs cross-linking was examined by enzyme-linked
immunosorbent assay (ELISA). KIOM-79 (50mg/kg/day) was given to Zucker diabetic fatty rats for 13 weeks. Body and kidney
weight, blood glucose, glycated hemoglobin, urinary albumin and creatinine excretions were monitored. Kidney histopathology,
collagen accumulation, ﬁbrinogen and transforming growth factor-beta 1 (TGF-β1) expression were also examined. KIOM-79
reduced blood glucose, kidney weight, histologic renal damage and albuminuria in Zucker diabetic fatty rats. KIOM-79 prevented
glomerulosclerosis, tubular degeneration, collagen deposition and podocyte apoptosis. In the renal cortex, TGF-β1, ﬁbronectin
mRNAandproteinweresigniﬁcantlyreducedbyKIOM-79treatment.KIOM-79reducesAGEsaccumulationinvivo,A GE-pr ot ein
cross-linking and protein oxidation. KIOM-79 could be beneﬁcial in preventing the progression of diabetic glomerularsclerosis in
type 2 diabetic rats by attenuating AGEs deposition in the glomeruli.
1.Introduction
Chronic hyperglycemia is a common feature of all forms of
diabetesmellitusandacceleratesnon-enzymaticbrowningin
the Maillard reaction between reducing sugars and free reac-
tive amino groups of proteins. The irreversible formation of
advanced glycation/lipoxidation end products (AGEs/ALEs)
aﬀects proteins and lipids such as hemoglobin, collagen and
lipoprotein and causes damage to the kidney, eyes and blood
vessels [1, 2]. Diabetic nephropathy is one of the main
causes of end-stage renal disease and is characterized by
proteinuria, progressive accumulation of glomerular extra-
cellular matrix (ECM) and glomerulosclerosis. The AGEs
inhibitors or cross-link breakers such as aminoguanidine
(AG), pyridoxamine, LR-90 and ALT-711 (alagebrium),
have been reported to attenuate various functional and
structural manifestations of diabetic microvascular disease
within the kidney in experimental animals [3–5]. There is
no Food and Drug Administration-approved agents for the
speciﬁc indication of AGEs modiﬁcation to date, although
these synthetic and natural compounds are in clinical and
preclinical testing [2]. The Zucker fatty rats, a widely studied
model of obesity and insulin resistance, exhibit glomerular
hypertrophy, thickening of basement membranes and diﬀuse
expansion of the glomerular mesangial matrix that resemble
some of the histologic changes seen in diabetic nephropathy
with proteinuria [6, 7].
Many traditional medicinal herbs have been used widely
for the treatment of diabetes and diabetic complications
in Asian countries for hundreds of years, and are still in
present use [8, 9]. In the past 5 years, extracts or single com-
pounds from herbs have been screened for possible AGEs
inhibitory or breaking eﬀects using various ﬂuorescence
and immunological techniques in our laboratory. KIOM-79
is composed of four herbal medicines, which are parched
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Figure 1: Inhibitory eﬀect of KIOM-79 on AGE-BSA and collagen cross-linking in vitro. Inhibition of KIOM-79 (a) and AG (b) on AGE-
BSA and collagen cross-linking. Breaking of KIOM-79 (c) and ALT-711 (d) on AGE-BSA and collagen cross-links. ∗∗∗P<. 001; ∗∗P<. 01
versus untreated group, respectively.
RadixandEuphorbiaeRadix[10].Previousstudiessuggested
that KIOM-79 possesses stronger inhibitory activity against
AGEs formation in vitro than the individual herbs or AG. It
alsoshowspharmacologicaleﬀectsondiabeticcomplications
in a non-obese rat model [11, 12]. Prevention of the
initiation of nephropathy or retardation of the progression
of glomerulosclerosis is important key for the development
of a therapeutic agent for renal disease. The aim of this
study was to examine the eﬀe c to fK I O M - 7 9 ,an e wh e r b a l
inhibitor of AGEs-protein cross-linking, on the progression
of diabetic nephropathy in Zucker diabetic fatty rats. KIOM-
79 demonstrated a protective eﬀect as measured by renal
functional and structural parameters, including TGF-β1a n d
the extracellular matrix proteins, such as ﬁbronectin and
collagen. We also found an anti-apoptotic eﬀect of KIOM-
79 in glomerular podocytes.
2. Methods
2.1. Materials. Cortex of Magnolia oﬃcinalis Rehd. et Wils.,
Radix of Pueraria lobata Ohwi, Radix of Glycyrrhiza uralensis
Fisch and Radix of Euphorbia pekinensis Ruprecht were
identiﬁed by botanist, Prof. J.H. Kim (Division of Life Sci-
ence, Daejeon University, Korea). These medicinal herbs that
constitute KIOM-79 were prepared as previously described
[10, 11]. The quality of KIOM-79 was controlled by HPLC
[11]. Biochemical reagents were from Sigma (St. Louis,
MO, USA) and antibodies from Cell Signaling or Santa
Cruz, unless otherwise indicated. All other chemicals were
of analytical grade.
2.2. In vitro Assay for Ages Inhibition/Breaking. For the
AGEs inhibition assay, AGE-BSA was incubated in either
the presence or absence of KIOM-79 or AG in collagen-
coated 96-well plates [13]. Collagen-AGE-BSA cross-linking
was detected using rabbit-anti-BSA antibody, horseradish
peroxidase-linked goat-anti rabbit IgG antibody and
H2O2 substrate containing ABTS chromogen. Inhibition
of collagen-AGE-BSA cross-linking was expressed as the
percentage decrease in optical density (OD = 410nm). We
calculated the IC50 concentration (μg/ml) as 50% inhibition
of collagen-AGE-BSA cross-linking. For the breaking assay,
AGE-BSA was pre-incubated on collagen-coated 96-well
plates for 24h and the collagen-AGE-BSA complexes wereEvidence-Based Complementary and Alternative Medicine 3
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Figure 2: Blood glucose levels and antioxidant eﬀect of KIOM-79 in serum of ZF rats. (a) Blood glucose; (b) antioxidant eﬀect in serum; (c)
TBARS levels in serum. ZL, normal lean rat; ZF, ZDF rat; ZF + AG, ZDF rat treated with AG (50mg/kg); ZF + KIOM-79, ZDF rat treated
with KIOM-79 (50mg/kg). All data are expressed as mean ± SD (n = 6, resp.). ∗∗∗P<. 001 versus ZL group; ∗P<. 05 versus ZF group.
incubated in either the presence or absence of KIOM-79
or ATL-711 [14]. Breaking levels were measured as the
percentage decrease in optical density (OD = 410nm).
ALT-711 was used as a positive control for AGEs cross-link
breaker.
2.3. Animals and Experimental Design. Male Zucker fatty
(fa/fa, ZF) and Zucker lean (fa/+ or +/+, ZL) rats were
obtained at 6 weeks of age from Charles River Laboratory
(Wilmington, MA, USA). Animals were divided into four
groups: Zucker lean rats (ZL, n = 7); Zucker fatty rats (ZF,
n = 7); Zucker fatty rats treated with AG (50mg/kg body
weight, ZF + AG, n = 7); Zucker fatty rats treated with
KIOM-79 (50mg/kg body weight, ZF + KIOM-79, n = 8).
Rats were allowed free access to water and food for 13 weeks
and, at 3 weeks intervals, their intake of water and food for
a 24-h period was measured. All experimental protocols for
animal care involving the use of animals were conducted
in accordance with National Institutes of Health (NIH)
Guidelines and approved by the Committee on Animal Care
of our institute.
2.4. Analysis of Metabolic Data. When the rats reached 20
weeksofage,bloodglucose,HbA1c(A1C),serumcreatinine,
total cholesterol, triglycerides, HDL, LDL and free fatty acid
were measured using an automated analyzer (Wako, Japan).
Blood samples were collected from the tail vein after a 16-h
fast. Individual rats were placed in metabolic cages to obtain
24-h urine collections and daily urinary albumin excretion
levels were measured.
2.5. Morphological Studies. R e n a lc o r t e x e sw e r eﬁ x e di n
10% formaldehyde and embedded in paraﬃn, and 4-μm
thick sections were prepared. The sections were stained
with periodic acid-Schiﬀ (PAS) reagent and hematoxylin
as a counterstain. Glomerular tuft and mesangial matrix
areas were measured using image analysis NIH Image J
software(NationalInstitutesofHealth,Bethesda,MD,USA).
The cross-section yielding the maximum diameter of the
glomerulus was photographed and converted into a digital
image. A total of 40 glomeruli were randomly chosen from
each rat kidney. To determine collagen deposition in the
kidneys, paraﬃns e c t i o n sw e r ed e p a r a ﬃnized, sectioned and4 Evidence-Based Complementary and Alternative Medicine
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Figure 3: Renal histopathology and function. (a) PAS staining of glomeruli. ×400; (b) glomerular volume in each group. Urine volume (c),
albuminuria (d) and creatinine clearance (CCR) (e). ZL, normal lean rat; ZF, ZDF rat; ZF + AG, ZDF rat treated with AG (50mg/kg); ZF +
KIOM-79, ZDF rat treated with KIOM-79 (50mg/kg). All data were expressed as mean ± SD (n = 6-7). ∗∗∗P<. 001 versus ZL; ##P<. 01;
#P<. 05 versus ZF group, respectively.
stained using Masson’s trichrome. For AGEs immnohisto-
chemistry, the deparaﬃnized sections were hydrated and
treated with 1% H2O2 in methanol. Sections were incubated
with anti-AGEs antibody (1:100, Transgenic Inc. Kobe,
Japan) for 2h at room temperature using a standard manual
immunoperoxidase procedure with streptavidin-peroxidase
(LSAB 2kit, Dako, CA, USA). The TUNEL assay was carried
out according to the manufacturer’s instructions (Roche
Diagnostics, Meylan, France). Kidney sections stained by
immunoﬂuorescence of synaptopodin (1:250) and Wilms
tumor antigen-1 (WT-1, 1:250) were observed by ﬂuo-
rescence microscopy (Olympus BX51) equipped with an
Olympus DP 70 camera.
2.6. RNA Extraction and RT-PCR. Total RNA isolation and
RT-PCR were as previously described [15]. For RT-PCR,Evidence-Based Complementary and Alternative Medicine 5
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Figure 4: Eﬀect of KIOM-79 on collagen accumulation and on expression of ﬁbronectin and TGF-β1 in the renal cortex of ZF rats. (a)
Masson’s trichrome stain shows collagen accumulation in the renal cortex from normal lean rat, ZF rat, ZF rat treated with AG (50mg/kg),
and ZF rat treated with KIOM-79 (50mg/kg). ×400. (b) Morphometric analysis of Masson’s trichrome-positive areas in renal cortex in each
group. The renal cortex from rats was immunoblotted using speciﬁc antibodies for ﬁbronectin (d) and TGF-β1 (g). Total RNA was isolated
and collagen III (c), ﬁbronectin (f) and TGF-β1 (h) expression were measured by RT-PCR. All data are expressed as mean ± SD (n = 6,
resp.).∗∗∗P<. 001 versus ZL group; ###P<. 001; ##P<. 01; #P<. 05, versus ZF group, respectively.6 Evidence-Based Complementary and Alternative Medicine
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Figure 5: Eﬀect of KIOM-79 on AGEs accumulation in the renal cortex of ZF rats. (a) Paraﬃn sections of kidney immunolabeled with AGEs
from ZL and ZF rats. (b) AGEs immunostaining was quantiﬁed after 13 weeks of treatment. ∗∗∗P<. 001 versus ZL group; ∗∗P<. 01 versus
ZF group.
cDNA was synthesized with 3μg of RNA using RT-primix
(Bioneer, Korea). The upstream and downstream primers
for rat TGF-β1m R N Aw e r e5  -CGA GGT GAC CTG GGC
ACC ATC CAT GAC-3  and 5 -CTG CTC CAC CTT GGG
CTT GCG ACC CAC-3 , yielding a 409-bp product. β-Actin
was used as an internal control, 5 -CGT AAA GAC CTC
TAT GCC AA-3  and 5 -AGC CAT GCC AAA TGT GTC AT-
3 , yielding a 350-bp product. The RT-PCR products were
separated by electrophoresis and DNA band intensities in
agarose gels and quantitated with densitometry (Las-3000,
Fuji photo, Tokyo, Japan).
2.7. Western Blot Analysis. Western blot was performed
using a previously described method [15]. Renal cortex
were lysed in solutions containing 250mM sucrose, 1mM
ethylenediaminetetraacetic acid (EDTA), 0.1mM phenyl-
methylsulfonyl ﬂuoride (PMSF) and 20mM potassium
phosphate buﬀer, at pH 7.6 with a homogenizer at 3000rpm.
Equal amounts of protein (50μg/lane) were subjected to
immunoblotting with the indicated antibodies. The anti-
bodies used were TGF-β1 and ﬁbronectin (1:1000, Santa
Cruz Biotechnology, CA, USA). The bound horseradish
peroxidase-conjugated secondary antibody was detected
using an enhanced chemiluminescence detection system
(iNtRON Biotechnology, Korea). Protein expression levels
were determined by analyzing the signals captured on the
nitrocellulose membranes using an image analyzer (Las-
3000, Fuji photo, Tokyo, Japan).
2.8. Statistical Analysis. Data are expressed as mean ± SD
and analyzed by one-way analysis of variance (ANOVA)
followed by Tukey’s multiple comparison test or by unpaired
Student’s t-test using GraphPad Prism 4.0 software (Graph
pad,SanDiego,CA,USA).DiﬀerenceswithavalueofP<. 05
were considered statistically signiﬁcant.
3. Results
3.1. Inhibitory Eﬀect of KIOM-79 on AGE-BSA and Collagen
Cross-Linking In Vitro. To investigate whether KIOM-79
could inhibit or break the AGEs cross-link, AGE-BSA was
incubated or pre-incubated with KIOM-79 in collagen-
coated plates. KIOM-79 (IC50 = 362.18μg/ml) exhibited
much stronger inhibitory activity on AGE-BSA binding
with collagen than AG (IC50 = 2.92mg/ml), a well-known
glycationinhibitor(Figures1(a)and1(b)).However,KIOM-
79 did not aﬀect AGEs breaking on the binding of AGE-BSA
and collagen (Figure 1(c)). Figure 1(d) shows the breaking
eﬀect of ALT-711 (IC50 = 16.50mg/ml), an AGEs cross-link
breaker.
3.2. Body Weight, Kidney Weight and Metabolic Parameters
in Blood. In ZF rats at 20 weeks of age, body weight was
increasedcomparedwithZLanddidnotchangecomparedto
rats that did not receive AG or KIOM-79 treatment. Kidney
weight was increased in ZF rats and reduced by KIOM-79
treatment (Table 1). Blood glucose, LDL, HDL, TG, totalEvidence-Based Complementary and Alternative Medicine 7
Table 1: Body weight and kidney weight of experimental rats.
ZL ZF ZF + AG ZF + KIOM-79
Body weight (g)
Initial 202.0 ± 24.4 276.6 ± 20.3 278.4 ± 9.1 266.5 ± 18.4
Final 338.5 ± 40.5 433.2 ± 69.4∗∗∗ 421.4 ± 66.1 414.6 ± 45.0
Kidney (mg/100 g body weight)
Left 280.9 ± 2.7 341.1 ± 19.0∗∗∗ 343.7 ± 26.8 316.6 ± 17.1∗
Right 302.6 ± 8.2 348.5 ± 25.9∗∗∗ 333.7 ± 26.2 320.1 ± 17.8∗
ZL: normal lean rat; ZF: ZDF rat; ZF+AG: ZDF rat treated with AG (50mg/kg); ZF+KIOM-79: ZDF rat treated with KIOM-79 (50mg/kg). All data were
expressed as mean ± SD.
∗∗∗ P<. 001 versus ZL group; ∗P<. 05 versus ZF group.
Table 2: Plasma chemistry of experimental rats.
ZL ZF ZF + AG ZF + KIOM-79
AST (U/l) 121.79 ± 16.10 177.70 ± 49.86 124.03 ± 16.09 137.61 ± 34.66
ALT (U/l) 48.49 ± 6.78 116.07 ± 17.23∗∗∗ 89.60 ± 26.12 105.76 ± 54.35
Total cholesterol (mg/dl) 100.61 ± 7.27 254.72 ± 18.13∗∗∗ 229.28 ± 43.65 228.33 ± 21.69
HDL-Chol (mg/dl) 34.59 ± 2.13 72.72 ± 6.88∗∗∗ 70.53 ± 15.77 68.24 ± 10.32
LDL-Chol (mg/dl) 8.64 ± 0.81 34.63 ± 6.47∗∗∗ 26.98 ± 9.84∗ 26.27 ± 7.88∗
Triglyceride (mg/dl) 93.09 ± 24.10 1112.60 ± 330.70∗∗∗ 817.12 ± 294.08∗ 881.04 ± 335.54∗
FFA (uEq/l) 896.29 ± 185.25 1775.83 ± 331.57 1677.67 ± 239.19 1224.14 ± 172.37∗∗
HbA1c (%) 3.71 ± 0.11 7.78 ± 1.19∗∗∗ 6.94 ± 1.07∗ 7.07 ± 0.61∗
ZL: normal lean rat; ZF: ZDF rat; ZF + AG: ZDF rat treated with AG (50mg/ml); ZF + KIOM-79: ZDF rat treated with KIOM-79 (50mg/kg). All data
were expressed as mean ± SD.
∗∗∗ P<. 001 versus ZL group; ∗P<. 05 versus ZF group; ∗∗P<. 01 versus ZF group.
cholesterol and HbA1c levels were signiﬁcantly increased in
ZF rats (P<. 001 versus control group). ZF rats treated
with AG or KIOM-79 showed signiﬁcant reduction in blood
glucose, LDL, TG and HbA1c as compared with untreated
ZF rats (Figure 2(a) and Table 2). However, no diﬀerences in
levels of liver enzymes, such as aspartate aminotransferase
(AST) and alanine aminotransferase (ALT), were noted
between treated and untreated ZF rats.
To determine the antioxidant eﬀect of KIOM-79 in
serum, antioxidant activity and malondialdehyde (MDA)
levels were tested. In ZF rats, the antioxidant levels signif-
icantly decreased (P<. 001) and MDA levels increased
(Figures 2(b) and 2(c)). KIOM-79 treatment signiﬁcantly
increased the reduced antioxidant enzyme activity and
decreased the elevated MDA levels.
3.3. Morphology and Renal Function. Mesangial matrix
expansion is considered a hallmark of diabetic nephropathy.
Figure 3(a) suggests accelerated mesangial matrix expansion
ascharacterizedinZFrats(arrow).Meanglomerularvolume
was determined by computer-assisted image analysis. ZF rats
revealed a greater than 32.7% increase in glomerular volume
comparedtoZLrats.AGorKIOM-79treatmentsigniﬁcantly
reduced the glomerular volume (Figure 3(b)). At 18 weeks
of age, ZF rats showed focal segmental glomerularsclerosis
(FSGS), tubulointerstitial damage, proteinuria and increased
kidney weight in contrast to age-matched ZL rats [7]. AG
and KIOM-79 treatment ameliorated glomerularsclerosis,
albuminuria and creatinine clearance, compared with the
untreated ZF rats (Figures 3(d) and 3(e)).
3.4. Expression of Collagen, Fibronectin and TGF-β1. To
investigate the eﬀect of KIOM-79 on expression of extra-
cellular matrix protein and mRNA, we measured collagen,
ﬁbronectin and TGF-β1 in renal tissue using immunoassay
and RT-PCR. Diabetic ZF rats were associated with an
increase in collagen protein expression in the glomeruli and
tubulointerstitium using Masson’s trichrome (Figures 4(a)
and4(b),P<. 001).Thedecreaseofcollagenintheglomeruli
was more prominent in diabetic ZF rats treated with AG and
KIOM-79 than in diabetic ZF rats (P<. 05, Figure 4(b)).
Speciﬁcally, extracellular matrix molecules, such as collagen
type III and ﬁbronectin mRNA expression were signiﬁcantly
decreased in diabetic ZF rats treated with AG and KIOM-
79 (Figures 4(c) and 4(f)). TGF-β1, a key regulator of
these extracellular matrix genes, has been implicated in the
pathogenesis of diabetic nephropathy [16]. Expressions of
TGF-β1 mRNA and protein were decreased in diabetic ZF
rats treated with AG and KIOM-79 (Figures 4(g) and 4(h)).
3.5. Quantitation of AGEs. Immunohistochemical staining
of AGEs in the glomeruli and tubulointerstitium demon-
strated a signiﬁcant increase in the ZF rats as compared with8 Evidence-Based Complementary and Alternative Medicine
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Figure 6:Anti-apoptoticeﬀect ofKIOM-79inthe renalpodocyte ofZFrats.(a) A representative photomicrograph ofTUNEL-positive cells,
synaptopodin, and WT-1 in the glomerulus. Renal cortex from rats was stained using speciﬁc antibodies for synaptopodin and WT-1, which
are speciﬁc markers of podocytes. Quantitative analyses of apoptotic cells (b), positive areas of synaptopodin (c) and positive cells of WT-1
(d). ∗∗∗P<. 001 versus ZL group; ∗∗P<. 01 versus ZF group.
the ZL rats. This was attenuated by both AG and KIOM-79
(Figures 5(a) and 5(b)).
3.6. Anti-Apoptotic Eﬀect of KIOM-79 in the Renal Podocytes
of ZF Rats. To determine the anti-apoptotic eﬀect of KIOM-
79, TUNEL assay was performed. In the ZF rats, TUNEL-
positive cells per glomerular section were signiﬁcantly
increased at 13 weeks of age compared with ZL rats (Figures
6(a)and6(b)).AGandKIOM-79treatmentswereeﬀectivein
reducing apoptosis in the diabetic ZF rats. Average numbers
of podocytes per glomerular section were determined by
counting cells and measuring areas that were positively
labeled with two podocyte markers, such as synaptopodin
and WT-1 [17, 18]. In ZF rats at age 20 weeks, synaptopodin
and WT-1 positive cell counts tended to decrease compared
with age-matched ZL rats. Treatment with AG and KIOM-
79 visibly increased the positive cells and areas in the kidney
glomeruli (Figures 6(a), 6(c),a n d6(d)).
4. Discussion
KIOM-79 is an 80% ethanolic extract of four herbal medici-
nals,whichareparchedPuerariaeRadix,gingeredMagnoliae
Cortex, Glycyrrhizae Radix and Euphorbiae Radix. TheseEvidence-Based Complementary and Alternative Medicine 9
herbal medicines are used frequently for the treatment of
diabetes or diabetic complications in traditional medicine
in Korea and other countries [8, 9]. Our previous studies
showed that KIOM-79 has anti-diabetic eﬀects, such as
protection of beta-cells, reduced glucose in non-obese type
2 diabetic rats, inhibition of AGEs formation in vitro
and anti-inﬂammatory eﬀects [10, 11, 19]. The results of
this study showed that KIOM-79, an herbal inhibitor of
AGEs-collagen cross-linking, reduced the development of
diabetic nephropathy in the type 2 diabetic animal model,
Zucker diabetic fatty rats. Based on immunohistochemical
measurements, the current study conﬁrmed that KIOM-
79 prevents AGEs accumulation in the diabetic kidney and
reduces hyperglycemia, apoptosis of podocyte and oxidation
in renal cortex. Furthermore, KIOM-79-treated diabetic
rats showed statistically signiﬁcant improvement in renal
functions such as albuminuria and creatinine clearance.
We have demonstrated that these eﬀects correlate with
preventionofseveralkeyaspectsofrenalpathologyinZucker
diabetic fatty rats.
A number of studies have shown that the hyperglycemia
has an important role in the pathogenesis of diabetic com-
plications by increasing protein glycation and the gradual
formation of AGEs in tissues, especially the kidney. There
is considerable interest in inhibitory compounds of AGEs-
protein cross-link formation or breaking because of their
therapeutic potential [2, 20]. Several natural and synthetic
compounds have been proposed and tested as inhibitors of
AGEs formation. AGEs inhibitors such as AG, pyridoxam-
ine, ALT-946 and LR-90 have been reported to attenuate
mesangial expansion and albuminuria in animal models of
diabetic renal disease [4, 20–26]. Furthermore, ﬂavonoids
such as oxerutin and disomin have demonstrated a capacity
to decrease the renal accumulation of AGEs and prevent
apoptosis of glomerular cells in diabetic nephropathy [24,
27]. The ﬂavonoids-induced decrease in glycation is associ-
ated with an increase in the antioxidant component [24].
In this study, KIOM-79, a natural product, inhibited
AGE-BSAandcollagencross-linkat8-foldlessconcentration
(IC50) than AG. However, it had no eﬀect on the breaking
of AGE-BSA and collagen cross-linking. KIOM-79-treated
ZF rats had antioxidant activity in serum and low blood
glucose when compared with untreated ZF rats. ALT-711,
an AGEs cross-link breaker, delayed established diabetic
nephropathy in db/db mice by reducing the systemic AGEs
pools and facilitating the urinary excretion of AGEs [5].
AGEs levels in glomerular section were signiﬁcantly reduced
in KIOM-79-treated ZF rats. The administration of KIOM-
79 signiﬁcantly ameliorated the ratio of kidney weight to
body weight in ZF rats. Kidney weight/body weight expresses
as a function of body weight, glomerular hypertrophy and
albuminuria in diabetic nephropathy. Furthermore, KIOM-
79 had inhibitory eﬀects on expression of TGF-β1a n d
ﬁbronectininrenalcortexandpodocyteapoptosis.Wefound
previously that KIOM-79 scavenges intracellular reactive
oxygen species (ROS) thereby preventing DNA damage.
Moreover, it inhibited apoptosis of beta-cells exposed to
streptozotocin via radical scavenging activity and activation
of antioxidant enzymes [19]. High glucose-induced ROS
promote podocyte apoptosis and AGEs accelerate podocyte
injury by activation of the FOXO4 transcription factor
[28]. Antioxidant therapy prevents podocyte apoptosis [2].
Our recent study showed that KIOM-79 prevented lens
opacity in xylose-induced lens through inhibition of aldose
reductase and reduction of reduced glutathione (GSH) [29].
Furthermore, KIOM-79 prevents cataracts, apoptosis in
neuronal cells of the retina and ameliorates the development
of diabetic retinopathy in animal models of type 2 diabetic
[30].
AGEs inhibitors are nucleophilic compounds designed
to trap reactive carbonyl or dicarbonyl intermediates in
AGEs formation and have potent chelating activity, making
it diﬃcult to dissect the antioxidative eﬀects [25]. The
mechanism of action of KIOM-79 in vivo is still is not clear.
However, KIOM-79iscomposed of naturalproductsandhas
been used widely for the treatment of diabetes. Based on our
ﬁndings, the inhibition of AGEs cross-linking in the kidney
and the antioxidant eﬀect on podocyte apoptosis by KIOM-
79 might ameliorate diabetic nephropathy and prevent the
progression to end-stage renal failure. Furthermore, these
data support the premise that KIOM-79 is eﬀective for
treatment for diabetic complications due to inhibition of
AGEs accumulation in the kidney.
In summary, this study showed that KIOM-79 is more
potent than previously used synthetic compound (such
as AG) on inhibition of AGE-protein cross-linking and
modulates the toxic eﬀects of AGEs in type 2 diabetic rats.
We speculate that KIOM-79 inhibits AGEs accumulation in
the renal cortex by direct or indirect interaction with AGEs-
proteincross-links.KIOM-79couldbeaneﬀectivetreatment
for diabetic nephropathy and possibly other complications.
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